{"entity":{"id":"marengo-therapeutics","kind":"company","name":"Marengo Therapeutics","aka":[],"tldr":"Marengo Therapeutics, of Cambridge, Massachusetts, makes antibodies that bind part of the T-cell receptor to activate selected subsets of a patient's T cells. Its lead, invikafusp alfa, is in trials in tumours with a high mutational burden that have stopped responding to checkpoint drugs, and with an antibody-drug conjugate in breast cancer.","summary":"Marengo Therapeutics is a clinical-stage Cambridge, Massachusetts company developing TCR-targeting antibodies that selectively modulate T-cell subsets. Its STAR platform (precision T-cell agonist) bispecifics include invikafusp alfa, in clinical development as monotherapy in immune checkpoint blockade-resistant, tumour mutational burden-high tumours (START-001) and in an antibody-drug conjugate combination in breast cancer (START-002), plus partnered STAR programmes. The TriSTAR platform (precision T-cell engager) includes TriSTAR0701 targeting Nectin-4 for bladder and other cancers and several partnered candidates, and the MSTAR platform (precision T-cell depleter) is aimed at autoimmune disease. Marengo's news page lists Apple Tree Partners as lead investor. Financing amounts and series were not stated on fetched pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://marengotx.com/"},{"label":"Pipeline","url":"https://marengotx.com/pipeline/"},{"label":"News and investors","url":"https://marengotx.com/news-investors/"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["immunotherapy"],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["nectin4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05592626","nct06827613"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced; press releases on the site are loaded client-side and could not be read."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://marengotx.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/marengo-therapeutics/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"}],"trial":[{"id":"nct05592626","kind":"trial","name":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","route":"/trials/nct05592626/"},{"id":"nct06827613","kind":"trial","name":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","route":"/trials/nct06827613/"}]}}